Arvaya Healthcare Limited Approves ₹210 Crore Rights Offer Draft

On November 4, 2026, Arvaya Healthcare Limited approved a draft letter of offer for a partly paid equity rights issue of up to ₹210 crore, moving its planned capital raise to the exchange-submission stage while leaving the issue price, entitlement ratio and call schedule undecided.

What did Arvaya Healthcare approve on November 4, 2026?

Arvaya Healthcare approved and adopted the draft letter of offer, or DLOF, for its proposed rights issue of partly paid equity shares. The proposed issue has an aggregate size of up to ₹210 crore, subject to full subscription, allotment and receipt of all call monies from shareholders.

The board outcome describes the proposed amount as ₹21,000 lakh, equivalent to ₹210 crore. The accompanying Regulation 30 disclosure also states that the proposed rights issue will not exceed ₹210 crore. The company has not disclosed the rights issue price, the number of shares to be issued, shareholder entitlement, record date or the instalment structure for the partly paid shares.

The draft offer document is intended to be submitted to BSE Limited, the designated stock exchange, for in-principle approval. The November 4 disclosure does not report that BSE has granted this approval. It records the board's decision to approve the document for submission.

How did the proposed rights issue progress?

The November 4 decision follows Arvaya Healthcare's board approval on July 11, 2026 for the underlying proposal to raise funds through a rights issue. The July decision authorised the company to pursue the proposed issue, while the latest board meeting approved the offer document needed for the next stage of the process.

On October 29, the company had informed BSE that its board would meet on November 4 to consider the DLOF, the objects and deployment of funds for the proposed rights issue, along with certain material related-party transactions. The board's final disclosure confirms the DLOF approval and the proposed issue ceiling.

The company said the rights issue is being undertaken under Section 62(1)(a) of the Companies Act, 2013 and the Securities and Exchange Board of India Issue of Capital and Disclosure Requirements Regulations, 2018. These provisions govern a company's ability to offer fresh shares to existing shareholders in proportion to their holdings, subject to the applicable process and disclosures.

Why is the issue structured as partly paid equity shares?

Arvaya Healthcare has proposed partly paid equity shares, meaning shareholders subscribing to the issue would not necessarily pay the entire issue price at the time of application. The company can call the remaining amount in one or more later instalments, according to the terms eventually set out in the final offer document.

The structure makes the final issue terms particularly important for investors. Until Arvaya Healthcare announces the price, ratio, total shares, application amount and future call amounts, the financial commitment for existing shareholders and the eventual dilution from the issue cannot be calculated from the disclosed information.

The board outcome was signed by Managing Director Kaushal Uttam Shah, with Pune recorded as the place of disclosure. Arvaya Healthcare also said that the outcome would be available on its website.

What other capital actions has Arvaya Healthcare taken recently?

Arvaya Healthcare has also undertaken a separate preferential allotment in October 2026. On October 24, the board approved the allotment of 38,71,854 equity shares at ₹40 each, aggregating to about ₹15.48 crore, to shareholders of Sushodha Institute of Gastroenterology Private Limited on a share-swap basis for non-cash consideration.

That preferential allotment is distinct from the proposed rights issue. The preferential issue involves shares issued to specified shareholders in connection with a transaction, while the rights issue is proposed as an offer to existing shareholders. The company had received BSE in-principle approval dated October 12 for the preferential issue, according to the disclosures provided.

Separately, Arvaya Healthcare has disclosed plans relating to acquisitions and a wholly owned insurance broking subsidiary. It has stated that the acquisition of the copyright and intellectual property portfolio of DEFIB Institute of Health Solutions LLP, for consideration not exceeding ₹10 crore, would be funded from rights issue proceeds. The detailed deployment of proceeds and the final rights issue terms remain subject to the offer process and applicable approvals.

What does the DLOF approval mean for shareholders and investors?

The DLOF approval means Arvaya Healthcare has advanced its fund-raising plan from an internal board proposal to a draft offer document that can be submitted to BSE. It does not mean that the issue has opened, that shares have been allotted, or that the company has received the proposed ₹210 crore.

For existing shareholders, the key forthcoming disclosures will be the issue price, rights entitlement ratio, record date, payment schedule and the stated use of proceeds. These details will determine the subscription commitment required to maintain ownership and the potential dilution for shareholders who do not participate.

For investors, the proposed maximum issue size is significant relative to the company's recent corporate actions, including the ₹15.48 crore preferential allotment. However, the actual capital raised will depend on subscription, allotment and the collection of all call monies. BSE's in-principle approval is also a necessary disclosed next step before the offer can progress.

Conclusion

Arvaya Healthcare has formally approved a draft offer document for a partly paid rights issue of up to ₹210 crore, following its July 2026 approval of the broader fund-raising proposal. The action establishes the proposed maximum size and advances the process toward stock-exchange review, but it does not disclose the commercial terms that shareholders need to assess participation.

The next items to watch are BSE's in-principle approval and Arvaya Healthcare's announcement of the issue price, entitlement ratio, record date, call-money schedule and detailed use of proceeds. The company's stated plans involving acquisitions and insurance broking make the eventual deployment disclosures relevant to shareholders evaluating the proposed capital raise.